Protalix BioTherapeutics (PLX) Asset Utilization Ratio (2011 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Asset Utilization Ratio of 0.83 for Q1 2026, up 1.94% year-over-year from 0.81 in Q1 2025, and up 29.08% quarter-over-quarter from 0.64 in Q4 2025.
Protalix BioTherapeutics (PLX) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
Protalix BioTherapeutics' Asset Utilization Ratio history runs 15 years deep, the most recent figure standing at 0.83 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 1.94% year-over-year to 0.83; the TTM figure through Mar 2026 stood at 0.83 (up 1.94% YoY), while the FY2025 annual figure was 0.68, changed 0.1% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.83, up from 0.64 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.87 in Q2 2023, with the low at 0.42 in Q2 2024.
- The 5-year median for Asset Utilization Ratio is 0.76 (2023), against an average of 0.73.
- The sharpest annual moves came in 2024 and 2025: Asset Utilization Ratio sank 51.8% in 2024, then soared 93.76% in 2025.
- Protalix BioTherapeutics' Asset Utilization Ratio stood at 0.85 in 2022, then declined by 10.08% to 0.76 in 2023, then gained by 3.9% to 0.79 in 2024, then slipped by 19.01% to 0.64 in 2025, then rose by 29.08% to 0.83 in 2026.
- Business Quant data shows PLX's Asset Utilization Ratio at 0.83 in Q1 2026, 0.64 in Q4 2025, and 0.77 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 0.13 |
| 10 | Protalix BioTherapeutics | 190.33 Mn | 149.67 Mn | 12.13 Mn | 0.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.76 |
| Mar 31, 2026 | 0.83 |
| Dec 31, 2025 | 0.64 |
| Sep 30, 2025 | 0.77 |
| Jun 30, 2025 | 0.81 |
| Mar 31, 2025 | 0.81 |
| Dec 31, 2024 | 0.79 |
| Sep 30, 2024 | 0.60 |
| Jun 30, 2024 | 0.42 |
| Mar 31, 2024 | 0.68 |
| Dec 31, 2023 | 0.76 |
| Sep 30, 2023 | 0.72 |
| Jun 30, 2023 | 0.87 |
| Mar 31, 2023 | 0.67 |
| Dec 31, 2022 | 0.85 |
| Sep 30, 2022 | 0.81 |
| Jun 30, 2022 | 0.70 |
| Mar 31, 2022 | 0.61 |
| Dec 31, 2021 | 0.49 |
| Sep 30, 2021 | 0.51 |